Business
Aileron Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
Initiated Phase 1b randomized, double-blind, placebo-controlled trial of ALRN-6924 in patients with advanced p53-mutated non-small cell lung cancer (NSCLC);
About this update from Rein Therapeutics, Inc.
[{"type":"text","content":"Initiated Phase 1b randomized, double-blind, placebo-controlled trial of ALRN-6924 in patients with advanced p53-mutated non-small cell lung cancer (NSCLC); first interim safety data expected at end of 2021 and topline results mid-2022 -- Announces upcoming presentations to highlight final data from Aileron’s completed Phase 1b trial of ALRN-6924 in patients with small cell lung cancer (SCLC) and initial findings from ongoing Healthy Volunteer Study of ALRN-6924 ISEH 2021 Virtual Scientific Meeting (August 25-28, 2021)ESMO Congress 2021 (September 16-21, 2021) -- ALRN-6924 is designed to deliver selective chemoprotection against chemotherapy-induced toxicities via p53 biomarker strategy Nearly 1 million patients in the U.S. across all cancer types are diagnosed annually with p53-mutated cancer -- $59.5 million cash and cash equivalents as of June 30, 2021, expected to fund operations into second half of 2023 BOSTON, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, today reported business highlights and financial results for the second quarter ended June 30, 2021. “Bolstered by a strong balance sheet and a healthy cash runway, we continue to execute against our clinical development strategy to advance selective chemoprotection for patients with p53-mutated cancer, including our initiation in the second quarter of our first randomized, double-blind, placebo-controlled clinical trial of ALRN-6924 for patients with p53-mutated non-small cell lung cancer (NSCLC),” said Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer at Aileron. Dr. Aivado continued, “The findings from this NSCLC trial will inform our late-stage clinical development strategy for ALRN-6924. Nearly 1 million cancer patients across all cancer types each year are diagnosed with p53-mutated cancer in the United States alone, and chemotherapy continues to be a cornerstone of cancer treatment for nearly every patient. As such, we believe that ALRN-6924 has the potential to protect many patients from chemotherapy-induced effects, thereby transforming their quality of life while they undergo chemotherapy and without reducing the effects of chemotherapy against cancer.” Aileron is developing ALRN-6924 to selectively ...